首页> 外文期刊>The annals of pharmacotherapy >Octreotide as a therapeutic option for management of chylothorax.
【24h】

Octreotide as a therapeutic option for management of chylothorax.

机译:奥曲肽作为乳糜胸的治疗选择。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To report a case of post-cardiac surgery-induced chylothorax treated with octreotide and review the literature on octreotide efficacy. CASE SUMMARY: A 5-month-old boy with Down syndrome was admitted for atrioventricular canal repair. On admission, he was taking captopril and furosemide. On postoperative day 4, he exhibited signs of chest wheezing and crackles, but was without cough or fever. Chest X-ray revealed a moderate right-sided pleural effusion. Accordingly, a pleural catheter was inserted and drained an average of 7.14 mL/h of chylous fluid that day. Laboratory analysis of the pleural fluid revealed a triglyceride level of 89 mg/dL, without bacterial growth. Based on those findings, the diagnosis was chylothorax. Because of the continuous extensive tube drainage, octreotide 3.5 micro g/kg/h was begun. The average daily chyle drainage was reduced from 7.14 one day before octreotide initiation to 0.83 mL/h on day 4 of octreotide therapy. After 4 days of therapy (postoperative day 8), octreotide was discontinued because of the satisfactory response and the pleural catheter was removed. DISCUSSION: In our case and the other few cases reported, octreotide showed acceptable efficacy in the management of chylothorax. The mechanism by which octreotide decreases chyle production includes reducing the intestinal absorption of fats, mainly triglycerides, and increasing fecal fat excretion. CONCLUSIONS: Octreotide may have reduced chyle production in our patient. Further reports and studies assessing octreotide efficacy in the management of chylothorax are warranted.
机译:目的:报道一例心脏手术后奥曲肽治疗乳糜胸的病例,并复习奥曲肽疗效的文献。病例摘要:患有唐氏综合症的5个月大男孩入院进行房室修复。入院时,他正在服用卡托普利和速尿。术后第4天,他表现出胸部喘息和crack裂的迹象,但没有咳嗽或发烧。胸部X光检查显示右侧胸腔积液。因此,当天插入胸膜导管并排出平均7.14 mL / h的乳状液。胸腔积液的实验室分析显示甘油三酯水平为89 mg / dL,无细菌生长。基于这些发现,诊断为乳糜胸。由于持续不断的大量引流,开始使用奥曲肽3.5 micro g / kg / h。平均每日乳糜排出量从奥曲肽开始前的7.14降低到奥曲肽治疗第4天的0.83 mL / h。治疗4天后(术后第8天),由于满意的反应而终止了奥曲肽并拔出了胸膜导管。讨论:在我们的病例和其他报道的病例中,奥曲肽在乳糜胸的治疗中显示出可接受的疗效。奥曲肽减少乳糜产生的机制包括减少肠道对脂肪(主要是甘油三酸酯)的吸收以及增加粪便脂肪的排泄。结论:奥曲肽可能降低了我们患者的乳糜产生。有必要进行进一步报告和评估奥曲肽在乳糜胸治疗中的功效的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号